Evidence map›Paper›PMID 30219309›Full record

ReviewTrends in immunology2018

Type III Interferons in Antiviral Defenses at Barrier Surfaces.

Alexandra I Wells, Carolyn B Coyne

Open access · greenAbstract readReview
In one paragraph

Review in Trends in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 149 citations in OpenAlex.

  1. Review
  2. Article
  3. Powassan Virus NS5 Antagonizes TYK2-Mediated Immune Signaling Pathways.bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Microbiota-dependent IFN-L controls uterine and placental immunity.bioRxiv : the preprint server for biology · 2026
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Alexandra I WellsDepartment of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Center for Microbial Pathogenesis, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15224, USA.
Carolyn B CoyneDepartment of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Center for Microbial Pathogenesis, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15224, USA. Electronic address: coynec2@pitt.edu.
Children's Hospital of Pittsburgh · USUniversity of Pittsburgh Medical Center · US

Funding

Enterovirus Infection of Polarized Intestinal CellsR01AI081759 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COYNE, CAROLYN B · 2009 to 2024
$5.0M
Primary human trophoblasts and the transfer of viral resistanceR01HD075665 · NICHD · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI COYNE, CAROLYN B, SADOVSKY, YOEL · 2012 to 2016
$2.4M
Molecular mechanisms of Toxoplasma-placenta interactionsR21AI139576 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BOYLE, JON P, COYNE, CAROLYN B · 2018 to 2019
$430k
NIAID NIH HHS R01 AI081759NIAID NIH HHS R21 AI139576NICHD NIH HHS R01 HD075665
6 · The paper itself

Abstract

Barrier surfaces such as the epithelium lining the respiratory and gastrointestinal (GI) tracts, the endothelium comprising the blood-brain barrier (BBB), and placental trophoblasts provide key physical and immunological protection against viruses. These barriers utilize nonredundant mechanisms to suppress viral infections including the production of interferons (IFNs), which induce a strong antiviral state following receptor binding. However, whereas type I IFNs control infection systemically, type III IFNs (IFN-λs) control infection locally at barrier surfaces and are often preferentially induced by these cells. In this review we focus on the role of IFN-λ at barrier surfaces, focusing on the respiratory and GI tracts, the BBB, and the placenta, and on how these IFNs act to suppress viral infections.

Indexed as

AnimalsBlood-Brain BarrierFemaleGastrointestinal TractHumansInterferon LambdaInterferonsPlacentaPregnancyRespiratory SystemSkin Physiological PhenomenaVirus DiseasesInterferon LambdaInterferonsbarrier surfacesinnate immunityinterferonplacenta

Identifiers

PMID30219309
PMCPMC6179363
OpenAlexW2889979622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.